Rhizoxin in Breast Cancer and Melanoma
Author Information
Author(s): A-R Hanauskel, G Catimel, S Aamdal, W ten Bokkel Huinink, R Paridaens, N Pavlidis, SB Kaye, A te Velde, J Wanders, J Verweij
Primary Institution: EORTC Early Clinical Trials Group
Hypothesis
Can rhizoxin achieve partial or complete remissions in patients with advanced breast cancer and melanoma?
Conclusion
Rhizoxin can be safely administered, but it has little activity in patients with advanced breast cancer and melanoma.
Supporting Evidence
- Rhizoxin was administered to 45 patients across two trials.
- Only minor responses were observed in breast cancer patients.
- No objective remissions were noted in melanoma patients.
- Haematological toxicities were the most common side effects.
- Patients with prior anthracycline treatment had poorer responses.
Takeaway
Rhizoxin is a new drug that was tested on patients with breast cancer and melanoma, but it didn't work well for them.
Methodology
Patients received rhizoxin as an intravenous infusion every 3 weeks, and their responses were evaluated after at least two courses of therapy.
Limitations
The study had a small sample size and did not include patients with extensive prior treatment.
Participant Demographics
{"breast_cancer":{"total_patients":19,"male_female_ratio":"0/17","age_median":56,"age_range":"34-72"},"melanoma":{"total_patients":26,"male_female_ratio":"16/10","age_median":54,"age_range":"24-76"}}
Statistical Information
Confidence Interval
95% CI: 0-22%
Want to read the original?
Access the complete publication on the publisher's website